Cemiplimab Biosimilar

Cemiplimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD1/CD279, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Cemiplimab is a fully human PD-1 antibody. The first indication for the marketing application is metastatic/locally advanced cutaneous squamous cell carcinoma (Cutaneous Squamous Cell Carcinoma, CSCC). It is an intravenous immunotherapy targeting the PD-1 pathway, which can help the immune system fight cancer cells.

Target	PDCD1/PD1/CD279
Research Area	Biosimilars
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG4 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life	12 months.
Buffer	0.01 M PBS, pH 7.4.
CAS Number	1801342-60-8
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 5-10 working days.
Note	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Research Articles on PDCD1/PD1/CD279

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue